相关实验视频
Updated: Jul 16, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
前期托法西提尼布在生物原始性性结肠炎患者中 - - 一个印度多中心体验
Suprabhat Giri1, Sukanya Bhrugumalla1, Abhishek Kamuni1
1Department of Gastroenterology, Nizam's Institute of Medical Sciences, Hyderabad, 500 082, India.
概括
托法西替尼 (tofacitinib) 能够有效地治疗生物素先验印度患者中中度至重度的性结肠炎 (UC). 这项研究表明,托法西提尼布是可行的选择,尽管需要进一步的研究.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 托法西提尼布是一种Janus激酶抑制剂,已被批准用于中度至重度UC,通常是在生物治疗失败后.
- 关于托法西提尼布在以前没有使用生物制剂的患者的疗效的数据有限.
研究的目的:
- 评估托法西替尼的安全性和有效性在生物素素的印度患者中,这些患者患有中度至重度的UC.
- 在这个人群中确定治疗反应的预测因素.
主要方法:
- 从六个印度三级医疗中心的47名生物素朴的UC患者进行了回顾性研究.
- 患者在2020年9月至2022年9月期间接受了托法西提尼布.
- 临床缓解和反应评估使用部分梅奥得分在第8,16和24周.
主要成果:
- 在8周后,70.2%的患者实现了临床缓解;基线血清白蛋白预测了这种反应.
- 到24周,59.6%的患者仍处于缓解状态,其中29.8%的患者因失败或不良事件而停止服用托法西替尼.
- 21.2%的不良事件发生,包括结核病和CMV结肠炎等感染.
结论:
- 前期托法西提尼布在生物素素的印度患者中表现出有效性,这些患者患有中度至重度UC.
- 基线血清白蛋白是早期缓解的重要预测指标.
- 需要进一步的随机对照试验来证实这些发现.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
168
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
168
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Inflammatory Bowel Disease I: Ulcerative Colitis
213
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
213

